Important: Models were tasked with extracting evidence from documents. Some outputs may be low quality and should be scored accordingly.
Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).
Evaluation scale (0-4):
Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.
INCLUSION CRITERIA 1. Histologically documented non-keratinizing locally advanced recurrent or metastatic NPC. 2. Must be resistant to platinum-based chemotherapy (defined as progression on or after platinum-based chemotherapy given in the recurrent/metastatic setting). 3. May have received at least 1 prior therapy for recurrent or metastatic disease, up to 2 prior systemic therapies. 4. An archival tumor specimen or newly obtained tumor sample may be submitted at screening/baseline (a fresh tumor sample is preferred), unless agreed differently between Novartis and the Investigator. 5. At least 1 measurable lesion (as per RECIST v1.1) progressing or new since last anti-tumor therapy. 6. Prior treated brain or meningeal metastases must be without MRI evidence of progression for at least 8 weeks and off systemic steroids for at least 2 weeks prior to screening/baseline. 7. Patient must be willing to undergo testing for human immunodeficiency virus (HIV) if not tested within the past 6 months. 8. If HIV+ positive, patient will be eligible if: his/ her CD4+ count ≥ 300/μL; his/her viral load is undetectable; he/she is currently receiving highly active antiretroviral therapy (HAART). EXCLUSION CRITERIA 1. History of severe hypersensitivity reactions to other mAbsActive autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved asthma/atopy that is treated with broncho-dilators. 2. Active HBV or HCV infections requiring therapy. 3. Prior PD-1- or PD-L1-directed therapy or any therapeutic cancer vaccine. 4. Patients receiving systemic treatment with any immunosuppressive medication. 5. Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment.
1 toxicity. 12. Previous use of any immunotherapy (monoclonal antibodies) for cancer, excluding prior use of anti-PD-1 or anti-PD-L1 antibodies. 13. Any prior exposure to experimental or investigational agents (including those under development) that are not part of standard treatment regimens. 14. Any prior exposure to radioactive substances (e.g., X-rays, positron emission tomography (PET), or radiotracemers) within the last 6 months. 15. Any prior exposure to non-steroidal anti-inflammatory drugs (NSAIDs) within the last 6 months. 14. Any prior exposure to other non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen, etc.) within the last 6 months. 16. Any prior exposure to corticosteroids within the last 6 months. 17. Any prior exposure to other corticosteroids (e.g., dexamethasone, hydrocortisone) within the last 6 months. 18. Any prior exposure to non-steroidal anti-inflammatory agents (e.g., ibuprofen, naproxen, etc.) within the last 6 months. 19. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 20. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 15. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 21. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 22. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 23. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 24. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 25. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 26. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 27. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 28. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 29. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 30. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 31. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 32. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 33. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 34. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 35. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 36. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 37. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 38. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 39. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 40. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 41. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 42. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 43. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 44. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 45. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 46. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 47. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 48. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 49. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 50. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 51. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 52. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 53. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 54. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 55. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 56. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 57. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 58. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 59. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 60. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 61. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept, darbepenem, etc.) within the last 6 months. 62. Any prior exposure to other non-steroidal anti-inflammatory agents (e.g., etanercept